Regenerative Medicine for the Durable Remission of HIV, Plasmid Infrastructure

We are developing a one-time treatment for durable remission of HIV in the absence of antiretroviral treatment. This treatment is a regenerative medicine therapy of autologous HIV-specific chimeric antigen receptor (CAR)-T cells that target B cell follicles, an immune protected site that permits viral replication.
Here, we propose to develop the infrastructure to produce GMP-ready plasmids, which will be used as starting materials for GMP manufacture of gammaretrovirus and CAR-T cells for the IND-enabling primate study and for the Phase 1 clinical trial.